Serina Therapeutics, Inc. Share-based Payment Arrangement, Expense in USD from 2017 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Serina Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2017 to Q3 2025.
  • Serina Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $999K, a 8.85% decline year-over-year.
  • Serina Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $3.83M, a 138% increase year-over-year.
  • Serina Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2.6M, a 10280% increase from 2023.
  • Serina Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $25K, a 96.7% decline from 2022.
  • Serina Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $760K, a 24.2% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Serina Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $3.83M $999K -$97K -8.85% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $3.93M $890K +$432K +94.3% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-11
Q1 2025 $3.5M $956K +$903K +1704% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-08
Q4 2024 $2.6M $988K +$987K +98700% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-24
Q3 2024 $1.61M $1.1M +$1.1M Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $512K $458K +$436K +1982% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-11
Q1 2024 $76K $53K +$51K +2550% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-08
Q4 2023 $25K $1K -$113K -99.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-24
Q3 2023 $138K $0 -$209K -100% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $347K $22K -$176K -88.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $523K $2K -$237K -99.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 $760K $114K -$153K -57.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 $913K $209K -$63K -23.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $976K $198K -$88K -30.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $1.06M $239K +$61K +34.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 $1M $267K Oct 1, 2021 Dec 31, 2021 10-K 2022-03-29
Q3 2021 $272K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 $286K Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-12
Q1 2021 $178K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2018 $184K $1K Oct 1, 2018 Dec 31, 2018 10-K/A 2020-03-31
Q3 2018 $33K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 $62K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 $88K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15

Serina Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $2.6M +$2.57M +10280% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-24
2023 $25K -$735K -96.7% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-24
2022 $760K -$243K -24.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-22
2021 $1M +$70K +7.5% Jan 1, 2021 Dec 31, 2021 10-K 2022-03-29
2020 $933K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-29
2018 $184K -$227K -55.2% Jan 1, 2018 Dec 31, 2018 10-K/A 2020-03-31
2017 $411K Jan 1, 2017 Dec 31, 2017 10-K 2019-04-01
* An asterisk sign (*) next to the value indicates that the value is likely invalid.